Additional Treatment Support
Additional Treatment Support
Once you have made the decision to prescribe TREMFYA®, Janssen CarePath provides support to help your patients get started and stay on track with their TREMFYA® treatment.
Janssen CarePath Patient Account
Patients and caregivers can create an online account at MyJanssenCarePath.com where they can learn about their health insurance coverage, enroll in the Janssen CarePath Savings Program and manage their benefits, sign up for treatment reminders, and find support throughout their treatment journey.
Safe Returns® Disposal
Safe Returns® is a simple, safe, and convenient way for your patients to dispose of their used syringes, at no additional cost. When they sign up, they’ll receive a Safe Returns® plastic disposal container in the mail, along with simple mail-back instructions.
- Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728) to help your patients sign up for the Safe Returns® program
TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
TREMFYA® is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.
WARNINGS AND PRECAUTIONS
TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.
Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.
Serious hypersensitivity reactions have been reported with postmarket use of TREMFYA®, some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.
Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.
Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.